Evidence map›Paper›PMID 40370471›Full record

ArticleFrontiers in immunology2025

Non-canonical extracellular complement pathways and the complosome paradigm in cancer: a scoping review.

Camila de Freitas Oliveira-Tore, Amarilis Giaretta de Moraes, Helena Musetti B S Plácido, Nathalia M D L Signorini, Pamela Dias Fontana, Tatiane da Piedade Batista Godoy, Angelica Beate Winter Boldt, Iara de Messias

Abstract readScoping Review
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Complement system in cancer: friend or foe of immunotherapy.Journal for immunotherapy of cancer · 2026
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Camila de Freitas Oliveira-ToreLaboratory Molecular Immunopathology, Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
Amarilis Giaretta de MoraesLaboratory Human Molecular Genetics, Postgraduate Program in Genetics, Department of Genetics, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
Helena Musetti B S PlácidoLaboratory Molecular Immunopathology, Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
Nathalia M D L SignoriniLaboratory Molecular Immunopathology, Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
Pamela Dias FontanaLaboratory Molecular Immunopathology, Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
Tatiane da Piedade Batista GodoyLaboratory Molecular Immunopathology, Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
Angelica Beate Winter Boldt *Laboratory Human Molecular Genetics, Postgraduate Program in Genetics, Department of Genetics, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
Iara de Messias *Laboratory Molecular Immunopathology, Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Complement System (CS) comprises three catalytic pathways that can be activated by specific immune triggers. However, within the tumor microenvironment (TME), CS intracellular components, recently named as complosome, play roles that extend beyond the activation and regulation of its pathways. The interaction between TME elements and tumor cells alters the local immune response, leading to inflammation, cell proliferation, and tumor invasion. Our focus is on understanding the significance of complosome and non-canonical pathways in cancer. In this scoping review, we analyzed 45 articles that discussed the various roles of CS components in carcinogenesis. Many CS components, including C1q, C3a-C3aR, C5a-C5aR, factor H, and properdin, some of them at the intracellular level, may play a dual role in tumor progression, demonstrating either anti-tumor or pro-tumor activity independent of complement pathway activation. The specific function of each component can influence both the type and stage of tumor cells. There is a notable lack of studies on the role of the lectin pathway in tumor development, and this knowledge gap must be addressed to fully understand the role of complosome in cancer. Nevertheless, the activation of CS and the roles of its components in complosome pathways are crucial steps in tumor development.

Indexed as

Complement ActivationComplement System ProteinsNeoplasmsTumor MicroenvironmentAnimalsHumansSignal TransductionComplement System ProteinsC1qC3C5cancercomplement systemnon-canonical activation pathway

Identifiers

PMID40370471
PMCPMC12075386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.